Loading...
•
Dec 31, 2019
Nektar Q4 2019 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2019.
Key Takeaways
Nektar Therapeutics reported a revenue of $33.9 million for the fourth quarter of 2019, compared to $39.8 million in the fourth quarter of 2018. The net loss for the quarter was $112.2 million, or $0.64 loss per share, compared to a net loss of $98.2 million, or $0.57 loss per share in the fourth quarter of 2018.
Cash and investments in marketable securities at December 31, 2019 were approximately $1.6 billion.
Amended joint development plan with Bristol-Myers Squibb for bempegaldesleukin in combination with Opdivo expands the active registrational program for the doublet to five indications.
Advanced NKTR-255, a novel IL-15 agonist that stimulates NK cells and memory T cells, into the clinic in combination with ADCC therapies.
Partner Eli Lilly is on track to initiate a Phase 2 study in lupus, advance ongoing Phase 1b clinical trials in psoriasis and atopic dermatitis, and start an additional Phase 2 study in a new autoimmune indication this year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...